

Study	Ottawa Newcastle Scale				Comparability	Exposure			RoBANS								
	Case-control Studies	Selection	1) case definition validation	2) Representativeness		3) selection of controls	4) definition of controls	1) Comparability of cases and controls	1) Ascertainment of Exposure	2) Same method of ascertainment for cases and controls	3) Non-response rate	Total N Stars	Selection of participants	Confounding Variables	Measurement of exposure	Outcome assessment	Incomplete outcome data
Booker 2016			*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Burton 2012			*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Davies 2011	*		*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Dregan 2015 anti-inflam drugs			*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Dunn 2005 Lithium	*		*	*	*	*	*	*	*		8	low risk	unclear risk	low risk	low risk	low risk	low risk
Dunn 2005 Infectious I*	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Imfeld 2012	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Imfeld 2013 Seizures	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Imfeld 2013 Epidemiol*	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Imfeld 2015	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Imfeld 2016	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Jick 2000	*		*	*	*	**	*	*	*		8	unclear risk	low risk	low risk	low risk	low risk	low risk
Ramakers 2007			*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Seshadri 2001	*		*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Wagner 2012			*	*	*	**	*	*	*		8	low risk	low risk	low risk	low risk	low risk	low risk
Cohort studies	Selection	1) Representativeness of the exposed cohort	2) Selection of non-exposed cohort	3) ascertainment of exposure	4) outcome not present at start	Comparability of cohorts on basis of design or analysis	Outcome Assessment of outcome	Follow up long enough >10 years	Adequacy of follow up	Total							
Buntinx 1996	*		*	*	*	**	*		*		8	low risk	low risk	low risk	low risk	low risk	low risk
Dregan 2015 inflamm:*	*		*	*	*	**	*		*		8	low risk	low risk	low risk	low risk	low risk	low risk
Kessing 2008	*		*	*	*	**	*		*		7	low risk	low risk	low risk	low risk	low risk	low risk
Koehler 2015	*		*	*	*	**	*	*	*		9	low risk	low risk	low risk	low risk	low risk	low risk
Walters 2016	*		*	*	*	*	*		*		8	low risk	unclear risk	low risk	low risk	low risk	low risk